Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Re: BMP-2 augmented fusion in the low-risk, healthy subjects: a confirmation of effectiveness and harms highlights the need for study in high risk patients.

Carragee EJ.

Spine (Phila Pa 1976). 2014 Feb 15;39(4):341-2. doi: 10.1097/BRS.0000000000000087. No abstract available.

PMID:
24162132
2.

Retrograde ejaculation after anterior lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a 10-year cohort controlled study.

Comer GC, Smith MW, Hurwitz EL, Mitsunaga KA, Kessler R, Carragee EJ.

Spine J. 2012 Oct;12(10):881-90. doi: 10.1016/j.spinee.2012.09.040.

PMID:
23098617
3.

Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review.

Garrison KR, Donell S, Ryder J, Shemilt I, Mugford M, Harvey I, Song F.

Health Technol Assess. 2007 Aug;11(30):1-150, iii-iv. Review.

4.

Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis.

Fu R, Selph S, McDonagh M, Peterson K, Tiwari A, Chou R, Helfand M.

Ann Intern Med. 2013 Jun 18;158(12):890-902. doi: 10.7326/0003-4819-158-12-201306180-00006. Review.

PMID:
23778906
5.

Complications related to osteobiologics use in spine surgery: a systematic review.

Mroz TE, Wang JC, Hashimoto R, Norvell DC.

Spine (Phila Pa 1976). 2010 Apr 20;35(9 Suppl):S86-104. doi: 10.1097/BRS.0b013e3181d81ef2. Review.

PMID:
20407355
6.

Does Bone Morphogenic Protein (BMP) Change the Operative Nonunion Rates in Spine Fusions?

Guppy K, Paxton L, Harris J, Alvarez J, Bernbeck J.

Spine (Phila Pa 1976). 2014 Jul 30. [Epub ahead of print]

PMID:
25077912
7.

Retrograde ejaculation after anterior lumbar spine surgery.

Lindley EM, McBeth ZL, Henry SE, Cooley R, Burger EL, Cain CM, Patel VV.

Spine (Phila Pa 1976). 2012 Sep 15;37(20):1785-9.

PMID:
22472808
8.

Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2--but what is the cost?

Mannion RJ, Nowitzke AM, Wood MJ.

Spine J. 2011 Jun;11(6):527-33. doi: 10.1016/j.spinee.2010.07.005.

PMID:
20739225
9.

The effects of lentiviral gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats.

Miyazaki M, Sugiyama O, Tow B, Zou J, Morishita Y, Wei F, Napoli A, Sintuu C, Lieberman JR, Wang JC.

J Spinal Disord Tech. 2008 Jul;21(5):372-9. doi: 10.1097/BSD.0b013e31814cf51d.

PMID:
18600149
10.

Fusion rates in multilevel, instrumented anterior cervical fusion for degenerative disease with and without the use of bone morphogenetic protein.

Frenkel MB, Cahill KS, Javahary RJ, Zacur G, Green BA, Levi AD.

J Neurosurg Spine. 2013 Mar;18(3):269-73. doi: 10.3171/2012.12.SPINE12607.

PMID:
23350532
11.

A comprehensive assessment of the risk of bone morphogenetic protein use in spinal fusion surgery and postoperative cancer diagnosis.

Cahill KS, McCormick PC, Levi AD.

J Neurosurg Spine. 2015 Jul;23(1):86-93. doi: 10.3171/2014.10.SPINE14338. Review.

PMID:
25860517
12.
13.

Use of bone morphogenetic proteins in spinal fusion surgery for older adults with lumbar stenosis: trends, complications, repeat surgery, and charges.

Deyo RA, Ching A, Matsen L, Martin BI, Kreuter W, Jarvik JG, Angier H, Mirza SK.

Spine (Phila Pa 1976). 2012 Feb 1;37(3):222-30. doi: 10.1097/BRS.0b013e31821bfa3a.

14.

Posterolateral lumbar fusion using Escherichia coli-derived rhBMP-2/hydroxyapatite in the mini pig.

Kong CB, Lee JH, Baek HR, Lee CK, Chang BS.

Spine J. 2014 Dec 1;14(12):2959-67. doi: 10.1016/j.spinee.2014.06.007.

PMID:
24937799
15.

Epidemiological trends in the utilization of bone morphogenetic protein in spinal fusions from 2002 to 2011.

Singh K, Nandyala SV, Marquez-Lara A, Fineberg SJ.

Spine (Phila Pa 1976). 2014 Mar 15;39(6):491-6. doi: 10.1097/BRS.0000000000000167.

PMID:
24365905
16.

Off-label use of bone morphogenetic proteins in the United States using administrative data.

Ong KL, Villarraga ML, Lau E, Carreon LY, Kurtz SM, Glassman SD.

Spine (Phila Pa 1976). 2010 Sep 1;35(19):1794-800. doi: 10.1097/BRS.0b013e3181ecf6e4.

PMID:
20700081
18.

Bone morphogenetic protein-associated complications in pediatric spinal fusion in the early postoperative period: an analysis of 4658 patients and review of the literature.

Rocque BG, Kelly MP, Miller JH, Li Y, Anderson PA.

J Neurosurg Pediatr. 2014 Dec;14(6):635-43. doi: 10.3171/2014.8.PEDS13665. Review.

PMID:
25303159
19.
20.

Enhancing effects of a prostaglandin EP4 receptor agonist on recombinant human bone morphogenetic protein-2 mediated spine fusion in a rabbit model.

Namikawa T, Terai H, Hoshino M, Kato M, Toyoda H, Yano K, Nakamura H, Takaoka K.

Spine (Phila Pa 1976). 2007 Oct 1;32(21):2294-9.

PMID:
17906568

Supplemental Content

Support Center